View More Guidelines in Heart Failure and Cardiac Biomarkers >

Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction

Dec 17, 2024   |  Anthony A. Bavry, MD,MPH,FACC

Clinical Trial

The goal of the PARAGON-HF trial was to evaluate the neprilysin-angiotension receptor inhibitor sacubitril/valsartan among patients with heart failure with preserved ejection fraction (HFpEF).

Clinical Topics: Heart Failure and Cardiomyopathies, Heart Failure and Cardiac Biomarkers

Keywords: ACC Annual Scientific Session, acc20, AHA19, AHA Annual Scientific Sessions, ESC 19, ESC24, ESC Congress, Heart Failure, Preserved Ejection Fraction, Neprilysin

NT-proBNP and Troponin I in Cardiac Function

Dec 10, 2024   |  Salim Hayek, MD, FACC

Journal Scan

How do N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) and I (hs-CTnI) predict long-term changes in cardiac structure and function in older adults?

Clinical Topics: Geriatric Cardiology, Noninvasive Imaging, Echocardiography/Ultrasound, Heart Failure and Cardiac Biomarkers

Keywords: Echocardiography, Geriatrics, Natriuretic Peptides, Troponin I

GLP-1 Receptor Agonists Along With SGLT2 Inhibitors for HFpEF

Nov 18, 2024   |  Julianne Fallon, PharmD

Journal Scan

What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2...

Clinical Topics: Cardiovascular Care Team, Heart Failure and Cardiac Biomarkers, Prevention

Keywords: Cardiometabolic Risk Factors, Glucagon-Like Peptide-1 Receptor, Heart Failure, Preserved Ejection Fraction, Sodium-Glucose Transporter 2 Inhibitors

Effects of Sacubitril/Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy

Nov 18, 2024   |  Amit Saha, MD

Clinical Trial

Editors' Pick

The goal of the SARAH trial was to assess the efficacy of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan in preventing anthracycline-associated cardiotoxicity.

Clinical Topics: Cardio-Oncology, Heart Failure and Cardiac Biomarkers, Prevention

Keywords: AHA24, AHA Annual Scientific Sessions, Anthracyclines, Cardio-oncology, Cardiotoxicity, Neoplasms

ENDEAVOR: Mitiperstat vs. Placebo in Patients With HFpEF or HFmrEF

Nov 18, 2024

ACC News Story

Myeloperoxidase inhibition with mitiperstat in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF, respectively) was safe and well-tolerated, but did not improve symptoms or exercise function...

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure, Heart Failure and Cardiac Biomarkers

Keywords: American Heart Association, AHA Annual Scientific Sessions, AHA24, Heart Failure, Peroxidase

Myeloperoxidase Inhibition With Mitiperstat in Heart Failure With Preserved and Mildly Reduced Ejection Fraction

Nov 18, 2024   |  Amit Saha, MD

Clinical Trial

The goal of the ENDEAVOR trial was to evaluate the effect of mitiperstat, a selective myeloperoxidase inhibitor, on symptom burden in patients with heart failure with preserved or moderately reduced ejection fraction (HFpEF or HFmrEF, respectively).

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure, Heart Failure and Cardiac Biomarkers

Keywords: AHA24, AHA Annual Scientific Sessions, Heart Failure, Peroxidase

View More Articles and Stories in Heart Failure and Cardiac Biomarkers >

Results 1-6 of 415

View More JACC Journals in Heart Failure and Cardiac Biomarkers >

View More Educational Activities in Heart Failure and Cardiac Biomarkers >

View More Meetings in Heart Failure and Cardiac Biomarkers >

View More Images and Slides in Heart Failure and Cardiac Biomarkers >

Date

View More Section News in Heart Failure and Cardiac Biomarkers >

View More Heart Failure and Cardiac Biomarkers Resources >